Why some rheumatoid arthritis patients respond poorly to biologics?

Primary tabs

Why some rheumatoid arthritis patients respond poorly to biologics?

A new study by Mayo Clinic probed on why some rheumatoid arthritis (RA) patients respond poorly when treated with tumor necrosis factor (TNF) inhibitors, that belongs to biologics. According to reserachers, it happens due to body protein in the body responsible for inflammation. So, in an attempt to eliminate “trial and error” prescribing of medications, a new step has been put forward for better personalizing RA treatment. The findings were presented at the American College of Rheumatology annual meeting in San Francisco.

Researchers showed that patients with a higher amount of an inflammatory protein called type 1 interferon beta do not respond to TNF inhibitors. They observed that white blood cells called monocytes, major cell type in RA pathogenesis and these cells behave differently in different subgroups of patients.

This new discovery paves the path for more accurate approach to treatRA based on the biology of a particular patient's disease. According to Theresa Wampler Muskardin, M.D., a rheumatologist at Mayo Clinic in Rochester, Minn, "Investigating these pathways may identify other targets for therapy or other markers that predict treatment response" He added, "It will help rheumatologists find the right drug for each patient and spare patients medications that won't work for them." The Rheumatology Research Foundation funded the study and authored by Mayo rheumatologist Timothy Niewold, M.D..

In other studies presented at the meeting, researchers found:

Sarcoidosis, the growth of tiny clusters of inflammatory cells called granulomas, carries a higher risk of heart disease and venous thromboembolism.

There is seasonal variation in the incidence of sarcoidosis: Rates are consistently lower in autumn.

Sarcoidosis may be triggered by the body's immune response to environmental factors, such as something inhaled from the air.

The risk of coronary artery disease among patients with polymyalgia rheumatica is 70%, which is higher than others.

Heart and circulatory abnormalities are common in Takayasu's arteritis, a form of vasculitis in which large blood vessels become inflamed.


Mayo Clinic

Link to the source:


Original title of article:

Why some rheumatoid arthritis patients respond poorly to biologics


Theresa Wampler Muskardin, Timothy Niewold

Mayo Clinic
Exploratory, Biologics, Rheumatoid arthritis, Tumor necrosis factor inhibitors, Review
Log in or register to post comments